Carcinoembryonic Antigen Market to Hit US$ 5.15 Billion by 2031 | Exclusive Report by Growth Plus Reports


Newark, New Castle, USA, June 13, 2023 (GLOBE NEWSWIRE) — The market analysis of the global carcinoembryonic antigen market was conducted by Growth Plus Reports in 2022 and was valued at US$ 2.66 billion. The market is expected to hit a revenue CAGR of 7.1% to reach US$ 5.15 billion by 2031.

Analysis of the global market for carcinoembryonic antigen indicates that the revenue share is likely to increase significantly. The glycoprotein known as carcinoembryonic antigen (CEA) is found in the tissues and physiological fluids of healthy persons in incredibly minute concentrations. 

Key Takeaways: 


  • The cancer prevalence worldwide is driving the market revenue share.
  • The introduction of precise and trustworthy diagnostic tools is driving the market demand.
  • The carcinoembryonic antigen industry trend is supported by government and business activities that increase awareness and make reimbursement procedures simple to access.

Get a Sample Copy of the Research Report:

                 Carcinoembryonic Antigen Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 2.66 billion
Revenue Forecast in 2031 US$ 5.15 billion
CAGR 7.1%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Test, Type, End User, And Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Carcinoembryonic Antigen Market: 

  • In May 2022, In order to specifically localize carcinoembryonic antigen (CEA) in formalin-fixed, paraffin-embedded (FFPE) tissue sections, BioGenex introduced anti-carcinoembryonic antigen (CEA) polyclonal antibody.

Competitive Landscape

A list of the companies operating in the global market for carcinoembryonic antigens includes: 

  • GenWay Biotech Inc.
  • Correlogic Systems, Inc.
  • Creative Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare GmbH

Market Drivers and Restraints: 

The global carcinoembryonic antigen market revenue is driven by cancer prevalence, diagnostic tool advancements, awareness among the population, and increasing research and developmental activities. 

However, due to the lack of specificity and several false positive results, the carcinoembryonic antigen market revenue growth is likely to be restrained. 

Market Segmentation: 

Segmentation By Test

Based on the test, the molecular tests segment dominates the global carcinoembryonic antigen market with the largest revenue share. This large revenue share is attributed to Molecular assays, such as polymerase chain reaction and next-generation sequencing, which have seen tremendous growth in the carcinoembryonic antigen industry because of their high sensitivity and specificity for cancer screening and surveillance.

Segmentation By Type

Based on the type, the colorectal cancer syndrome segment dominates the global carcinoembryonic antigen market with the largest revenue share. The significant rise in revenue share is attributed to it being the most prevalent type of cancer globally, and A known biomarker for the identification and monitoring of colorectal cancer is a carcinoembryonic antigen.

Segmentation By End User 

Based on end-user, the ophthalmic clinic’s segment accounts for the highest share of revenue in the global carcinoembryonic antigen market. Since hospitals are the principal settings with well-equipped infrastructure and skilled staff for cancer detection and treatment, they have made a sizable financial contribution to the carcinoembryonic antigen industry.

Request for Customization –

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global carcinoembryonic antigen market. The area boasts a robust healthcare system and simple access to innovative tools for detecting and treating cancer. The rising incidence of cancer in North America, notably in the United States, has been a major factor in the need for carcinoembryonic antigen testing.

Report Coverage 

Growth Plus Reports carried out extensive market research on the carcinoembryonic antigen market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Molecular Tests
    2. Serology Tests
    1. Colorectal Cancer
    2. Pancreatic Cancer
    3. Ovarian Cancer
    4. Breast Cancer
    5. Thyroid Cancer
    6. Others
    1. Hospitals
    2. Diagnostic Laboratories
    3. Others 


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Anticholesteremic Agents Market by Drug Class (Bile Acid Resins, Statins), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

Expat Health Insurance Market by Service Provider (Private, Public), Indication (Emergency Medical Evacuation, Maternity Coverage, Outpatient Coverage), Term Plan (Short-Term, Long-Term) – Global Outlook & Forecast 2023-2031

Veterinary Euthanasia Drugs Market by Animal Type (Companion Animals and Farm Animals), Route of Administration (Injectable Euthanasia Drugs, Inhalational Euthanasia Drugs) – Global Outlook & Forecast 2023-2031

MISME Syndrome Market by Treatment (Surgery, Radiotherapy, Pharmacotherapy) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.